Determinants of RASistance to anti-epidermal growth factor receptor agents

Journal of Clinical Oncology

Volumn 26, Issue 10, 2008, Pages 1582-1584

  Baselga, José ^a   Rosen, Neal ^b  

^a VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; RAS PROTEIN;

ADVANCED CANCER; BILIARY TRACT CANCER; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; DISEASE FREE SURVIVAL; EDITORIAL; ENDOMETRIUM CANCER; GENE MUTATION; HEAD AND NECK CANCER; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MONOTHERAPY; ONCOGENE K RAS; ONCOGENE N RAS; PANCREAS CANCER; PRIORITY JOURNAL; TREATMENT OUTCOME; UTERINE CERVIX CANCER; DRUG ANTAGONISM; DRUG RESISTANCE; GENETICS; METABOLISM; MUTATION; NEOPLASM; NOTE; RANDOMIZED CONTROLLED TRIAL;

DRUG RESISTANCE, NEOPLASM; HUMANS; MUTATION; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 43249110658     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.15.3700     Document Type: Editorial

References (22)

1. Mendelsohn J, Baselga J: Epidermal growth factor receptor targeting in cancer. Semin Oncol 33:369-385, 2006
2. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345, 2004
3. Van Cutsem E, Peeters M, Siena S, et al: Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658-1664, 2007
4. Khambata-Ford S, Garrett CR, Meropol NJ, et al: Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25:3230-3237, 2007
5. Downward J: Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3:11-22, 2003
6. Schubbert S, Shannon K, Bollag G: Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 7:295-308, 2007
7. Malumbres M, Barbacid M: RAS oncogenes: The first 30 years. Nat Rev Cancer 3:459-465, 2003
8. Izumi Y, Hirata M, Hasuwa H, et al: A metalloprotease-disintegrin, MDC9/meltrin-gamma/ADAM 9 and PKC delta are involved in TPA-induced ectodomain shedding of membrane-anchored heparin-binding EGF-like growth factor. EMBO J 17:7260-7272, 1998
9. Forbes S, Clements J, Dawson E, et al: Cosmic 2005. Br J Cancer 94:318-322, 2006
10. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al: Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti- epidermal growth factor receptor antibody therapies. Cancer Res 67:2643-2648, 2007
11. Di Fiore F, Blanchard F, Charbonnier F, et al: Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer 96:1166-1169, 2007
12. Lievre A, Bachet JB, Le Corre D, et al: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66:3992-3995, 2006
13. De Roock W, Piessevaux H, De Schutter J, et al: KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol [epub ahead of print on November 12, 2007]
14. Amado RG, Wolf M, Peeters M, et al: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer: Results from a phase III trial of panitumumab compared to best supportive care. J Clin Oncol 26:1626-1634, 2008
15. Bowtell DD: Options available -from start to finish- for obtaining expression data by microarray. Nature 21:25-32, 1999 (suppl)
16. Pao W, Wang TY, Riely GJ, et al: KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2:e17, 2005
17. Massarelli E, Varella-Garcia M, Tang X, et al: KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 13:2890-2896, 2007
18. Miller VA, Zakowski M, Riely GJ, et al: EGFR mutation and copy number, EGFR protein expression and KRAS mutation as predictors of outcome with erlotinib in bronchioloalveolar cell carcinoma (BAC): Results of a prospective phase II trial. J Clin Oncol 24:364s, 2006 (abstr 7003)
19. Eberhard DA, Johnson BE, Amler LC, et al: Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non- small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23:5900, 2005
20. Philip PA, Benedetti J, Fenoglio-Preiser C, et al: Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study. J Clin Oncol 25:199s, 2007 (abstr LBA4509)
21. Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966, 2007
22. Mellinghoff IK, Wang MY, Vivanco I, et al: Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353:2012-2024, 2005